查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1363084

大腸直腸癌治療藥物市場規模、佔有率和趨勢分析報告：按藥物類別、地區和細分市場預測，2023-2030年

Colorectal Cancer Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Chemotherapy, Immunotherapy), By Region (North America, Asia Pacific, Latin America, Europe), And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

大腸直腸癌治療藥物市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，全球大腸癌治療市場規模將達到167億美元，2023年至2030年年複合成長率為4.7%。

預計有幾個要素將推動市場成長，例如增加目標人口和增加標靶治療的採用。

正在研發的產品旨在滿足大腸直腸癌 (CRC) 市場中一些未滿足的需求。如果核准，Array Biopharma 的西妥昔單抗和 encorafenib聯合治療將成為第一個用於治療 BRAF 突變 mCRC 的療法。 Sumitomo Dainippon Pharma 的 napabucasin 是一種針對 STAT-3 的癌症幹細胞抑制劑。

可切除的高危險性大腸直腸癌的輔助/新輔助治療很少。在這種情況下，管道藥物的缺乏是開發有效治療方法的絕佳機會，可以提高切除患者的治癒率。目前，大多數可切除大腸直腸癌的可用治療方法都是廉價的化療方案和學名藥。

隨著羅氏的阿瓦斯汀、安進的 Vectibix 和賽諾菲的 Zaltrap 等主要產品的專利到期，生物相似藥預計將變得更加普遍。安進/艾爾建 (Amgen/Allergan) 的 Mvasi 是第一個於 2017 年在美國獲得核准、於 2018 年在歐洲獲得批准的阿瓦斯汀生物學名藥。 Cizumab 和 Claveva 是在印度推出的 Avastin 生物相似藥之一。其他幾種阿瓦斯汀和愛必妥生物學名藥正在開發中。

大腸直腸癌治療藥物市場報告亮點

  • 由於阿瓦斯汀 (Avastin) 和愛必妥 (Erbitux) 等標靶治療的採用增加，到 2022 年，免疫療法將在藥物類別市場中佔據主導地位。
  • 由於非特異性、副作用和抗藥性的開拓，化療可能會失去市場佔有率。然而，隨著最近Opdivo和Keytruda等抗PD1藥物的上市及其針對性的作用機制，目前的情況可能會改變。
  • 按國家分類，美國擁有最大的市場佔有率，由於疾病負擔增加、治療率上升和藥物成本急劇上升，預計到 2022 年將保持主導地位。
  • 由於阿瓦斯汀的使用量增加，2022 年羅氏在大腸癌產業中處於領先地位。阿瓦斯汀是 2022 年銷售額最高的大腸直腸癌藥物。然而，由於阿瓦斯汀的專利到期和生物相似藥的滲透，羅氏預計將失去市場佔有率。
  • 在 Opdivo 和 Keytruda 等標靶治療的採用增加的推動下，百時美施貴寶和默克預計到 2022 年將成為結直腸癌藥物市場的市場領導者。

目錄

第1章 調查方法和範圍

第2章 執行摘要

第3章 大腸直腸癌治療藥物市場的變數、趨勢和範圍

  • 市場體系預測
    • 母市場預測
    • 相關/附隨市場預測
  • 普及和成長預測圖
  • 市場動態
    • 市場促進因素分析
    • 市場抑制因素分析
  • 大腸直腸癌治療藥物市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章 結直腸癌治療藥物市場：按藥物類別估計和趨勢分析

  • 大腸直腸癌藥物市場：重點
  • 大腸直腸癌藥物市場：2022 年和 2030 年趨勢和市場佔有率分析
  • 化療
  • 免疫療法
  • 其他

第5章 結直腸癌治療藥物市場：區域估計和趨勢分析

  • 區域預測
  • 按地區分類的結直腸癌藥物市場：要點
  • 北美洲
    • 2018-2030 年市場估計與預測
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 泰國
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第6章 競爭形勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 市場參與企業分類
    • Amgen, Inc.
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Lilly
    • Merck & co., Inc.
    • F. Hoffmann-La Roche Ltd
    • Sanofi
Product Code: GVR-2-68038-512-0

Colorectal Cancer Therapeutics Market Growth & Trends:

The global colorectal cancer therapeutics market size is expected to reach USD 16.7 billion by 2030, according to a new report by Grand View Research, Inc.., exhibiting a CAGR of 4.7% from 2023 to 2030. Several factors such as increasing target population and rising adoption of targeted therapies are anticipated to fuel market growth.

Products in the pipeline are striving to meet some of the unmet needs of the colorectal cancer (CRC) market. If approved, Array Biopharma's cetuximab plus encorafenib would become the first therapy indicated for BRAF-mutant mCRC treatment. Sumitomo Dainippon's Napabucasin is a cancer stem cell inhibitor targeting STAT-3.

There are few available adjuvant/neoadjuvant medicines for treatment of high-risk resectable colorectal cancer. Lack of pipeline agents in this setting presents a good opportunity for development of effective treatments that can improve cure rates for resected patients. At present, most available treatments for resectable CRC include cheaper chemotherapeutic regimens and generics.

Upcoming patent expiries of key products such as Roche's Avastin, Amgen's Vectibix, and Sanofi's Zaltrap will lead to biosimilar penetration. Amgen/Allergan's Mvasi marked the first Avastin biosimilar approval in U.S. and Europe in 2017 and 2018, respectively. Cizumab and Krabeva are some of the biosimilars to Avastin launched in India. Several other biosimilars to Avastin and Erbitux are under development.

Colorectal Cancer Therapeutics Market Report Highlights:

  • Immunotherapy dominated the market based on drug class in 2022, owing to increasing adoption of targeted therapies such as Avastin and Erbitux
  • Chemotherapy is likely to lose market share on account of non-specificity, adverse effects, and development of resistance to chemical agents. However, recent launch of anti-PD1 drugs such as Opdivo and Keytruda is likely to change the current landscape due to their target-oriented mechanism of action
  • U.S. accounted for the largest share based on country and is projected to maintain its dominance through to 2022 owing to growing disease burden, increasing treatment rate, and high cost of drugs
  • Roche led the colorectal cancer industrial setting in 2022 due to growing usage of Avastin. Avastin was the highest revenue-generating CRC medicine in 2022. However, Roche is projected to lose market share on grounds of Avastin's patent expiry and biosimilar penetration
  • Bristol-Myer Squibb and Merck are anticipated to be market leaders in the colorectal cancer drugs market space by 2022 due to increasing adoption of targeted therapies such as Opdivo and Keytruda.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Drug class
    • 1.1.2. Regional scope
    • 1.1.3. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug class outlook
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Colorectal Cancer Therapeutics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
    • 3.3.2. Market Restraint Analysis
  • 3.4. Colorectal Cancer Therapeutics Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic Landscape

Chapter 4. Colorectal Cancer Therapeutics Market: Drug Class Estimates & Trend Analysis

  • 4.1. Colorectal Cancer Therapeutics Market: Key Takeaways
  • 4.2. Colorectal Cancer Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Chemotherapy
    • 4.3.1. Chemotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Immunotherapy
    • 4.4.1. Immunotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Others
    • 4.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Colorectal Cancer Therapeutics Market: Regional Estimates & Trend Analysis

  • 5.1. Regional Outlook
  • 5.2. Colorectal Cancer Therapeutics Market by Region: Key Takeaway
  • 5.3. North America
    • 5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.3.2. U.S.
      • 5.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.3.3. Canada
      • 5.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.4. Europe
    • 5.4.1. UK
      • 5.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.2. Germany
      • 5.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.3. France
      • 5.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.4. Italy
      • 5.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.5. Spain
      • 5.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.6. Denmark
      • 5.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.7. Sweden
      • 5.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.8. Norway
      • 5.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.5. Asia Pacific
    • 5.5.1. Japan
      • 5.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.2. China
      • 5.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.3. India
      • 5.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.4. Australia
      • 5.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.5. Thailand
      • 5.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.6. South Korea
      • 5.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.6. Latin America
    • 5.6.1. Brazil
      • 5.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.6.2. Mexico
      • 5.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.6.3. Argentina
      • 5.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.7. MEA
    • 5.7.1. South Africa
      • 5.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.2. Saudi Arabia
      • 5.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.3. UAE
      • 5.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.4. Kuwait
      • 5.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Market Participant Categorization
    • 6.2.1. Amgen, Inc.
      • 6.2.1.1. Company Overview
      • 6.2.1.2. Financial performance
      • 6.2.1.3. Product benchmarking
      • 6.2.1.4. Strategic initiatives
    • 6.2.2. Bayer AG
      • 6.2.2.1. Company overview
      • 6.2.2.2. Financial performance
      • 6.2.2.3. Product benchmarking
      • 6.2.2.4. Strategic initiatives
    • 6.2.3. Bristol-Myers Squibb Company
      • 6.2.3.1. Company overview
      • 6.2.3.2. Financial performance
      • 6.2.3.3. Product benchmarking
      • 6.2.3.4. Strategic initiatives
    • 6.2.4. Lilly
      • 6.2.4.1. Company overview
      • 6.2.4.2. Financial performance
      • 6.2.4.3. Product benchmarking
      • 6.2.4.4. Strategic initiatives
    • 6.2.5. Merck & co., Inc.
      • 6.2.5.1. Company overview
      • 6.2.5.2. Financial performance
      • 6.2.5.3. Product benchmarking
      • 6.2.5.4. Strategic initiatives
    • 6.2.6. F. Hoffmann-La Roche Ltd
      • 6.2.6.1. Company overview
      • 6.2.6.2. Financial performance
      • 6.2.6.3. Product benchmarking
      • 6.2.6.4. Strategic initiatives
    • 6.2.7. Sanofi
      • 6.2.7.1. Company overview
      • 6.2.7.2. Financial performance
      • 6.2.7.3. Product benchmarking
      • 6.2.7.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 North America colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 3 North America colorectal cancer therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 4 U.S. colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 5 Canada colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 6 Europe colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 7 Europe colorectal cancer therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 8 Germany colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 9 UK colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 10 France colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 11 Italy colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 12 Spain colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 13 Sweden colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 14 Norway colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 15 Denmark colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 16 Asia Pacific colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 17 Asia Pacific colorectal cancer therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 18 Japan colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 19 China colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 20 India colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 21 Australia colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 22 Thailand colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 23 South Korea colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 24 Latin America colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 25 Latin America colorectal cancer therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 26 Brazil colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 27 Mexico colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 28 Argentina colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 29 Middle East and Africa colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 30 Middle East and Africa colorectal cancer therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 31 South Africa colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 32 Saudi Arabia colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 33 UAE colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 34 Kuwait colorectal cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Colorectal cancer therapeutics: Market outlook
  • Fig. 9 Colorectal cancer therapeutics: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Colorectal cancer therapeutics market driver impact
  • Fig. 15 Colorectal cancer therapeutics market restraint impact
  • Fig. 16 Colorectal cancer Therapeutics market strategic Initiatives analysis
  • Fig. 17 Colorectal cancer therapeutics market: Drug class movement analysis
  • Fig. 18 Colorectal cancer therapeutics market: Drug class outlook and key takeaways
  • Fig. 19 Immunotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Chemotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Other market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Global Colorectal Cancer Therapeutics market: Regional Movement Analysis
  • Fig. 23 Global Colorectal cancer therapeutics market: Regional outlook and key takeaways
  • Fig. 24 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)